[Diabetic macroangiopathy and NO].
Hayashi
Toshio
T
Department of Geriatrics, Nagoya University Graduate School of Medicine.
Iguchi
Akihisa
A
D000818:Animals; D001708:Biopterins / Q000031:analogs & derivatives* / Q000502:physiology; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000503:physiopathology; D004967:Estrogens / Q000502:physiology; D005260:Female; D005609:Free Radicals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D019255:NADPH Oxidases / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000502:physiology; D052250:Nitric Oxide Synthase Type III; D018384:Oxidative Stress; D017382:Reactive Oxygen Species; D012307:Risk Factors; D012727:Sex Characteristics
D004967:Estrogens; D005609:Free Radicals; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017382:Reactive Oxygen Species; D001708:Biopterins; D009569:Nitric Oxide; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D019255:NADPH Oxidases; C003402:sapropterin